
JonesTrading analyst Debanjana Chatterjee has maintained their neutral stance on SION stock, giving a Hold rating on November 10. Debanjana Chatterjee’s rating is based on several factors, including Sionna’s disappointing
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| SION | Sionna Therapeutics, Inc. | 2.83 | -40.83 | -93.53% |
| Name | Price | % Change | |
|---|---|---|---|
| $2.83 | -93.53% |

JonesTrading analyst Debanjana Chatterjee has maintained their neutral stance on SION stock, giving a Hold rating on November 10. Debanjana Chatterjee’s rating is based on several factors, including Sionna’s disappointing

“During the third quarter, we established a focused path forward for Sionna centered on SION-451 + SION-2222, our proprietary, NBD1-anchored dual combination,” said Mike Cloonan, President and Chief Executive Officer

Sionna Therapeutics, Inc. (SION) is scheduled to report 3rd quarter earnings on 11/11/2026. Regarding Q3 estimates, Wall Street analysts expect Sionna Therapeutics, Inc. to post earnings of -$0.64 per share.

Sionna Therapeutics (SION) “announced data being presented at the 2026 North American Cystic Fibrosis Conference (NACFC) being held in Atlanta, Georgia on October 7-10, 2026. The oral presentation by Dr.

Wedbush raised the firm’s price target on Sionna Therapeutics (SION) to $6 from $5 and keeps a Neutral rating on the shares. The firm notes the company released additional post

Sionna Therapeutics, Inc. ( ($SION) ) has provided an update. On September 9, 2026, Sionna’s board approved a restructuring plan that will cut about 46% of its workforce, wind down

Sionna Therapeutics (SION) announced plans to advance SION-451 + SION-2222, its preferred proprietary dual combination, into the AscenSION CF Phase 2a proof-of-concept, or POC, trial, and results from the company’s

Following the completion of a comprehensive review of its operations, Sionna’s board of directors has approved a workforce reduction of approximately 46% and the company has implemented other cost-saving measures

Sionna Therapeutics (SION) is up 15.9%, or 71c to $5.21. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks

Freedom Broker analyst Ilya Zubkov lowered the firm’s price target on Sionna Therapeutics (SION) to $5 from $38 and keeps a Hold rating on the shares, telling investors that the
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| hold | Reiterated | Nov 20, 2026 | ||||
| buy | Reiterated | Nov 11, 2026 | ||||
| hold | Reiterated | Nov 10, 2026 | ||||
| hold | Reiterated | Nov 10, 2026 | ||||
| hold | Reiterated | Sep 19, 2026 | ||||
| hold | Reiterated | Sep 15, 2026 | ||||
| hold | Reiterated | Sep 15, 2026 | ||||
| hold | Reiterated | Sep 15, 2026 | ||||
| hold | Reiterated | Aug 11, 2026 | ||||
| hold | Downgraded | Aug 10, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 25, 2027TBA | $134.35M | $-0.59 | $0.00 | -0.64 | -1.16 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.